Evidence map›Paper›PMID 39290148›Full record

ReviewEssays in biochemistry2024

A comparative guide to expression systems for phage lysin production.

Emma Cremelie, Roberto Vázquez, Yves Briers

Abstract readReviewComparative Study
In one paragraph

Review in Essays in biochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Phage-Derived Endolysins TargetingAntibiotics (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. The new age of the phage.Essays in biochemistry · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Emma CremelieLaboratory of Applied Biotechnology, Department of Biotechnology, Ghent University, Ghent, Belgium.ORCID 0000-0003-0957-1443
Roberto VázquezLaboratory of Applied Biotechnology, Department of Biotechnology, Ghent University, Ghent, Belgium.ORCID 0000-0002-7919-552X
Yves BriersLaboratory of Applied Biotechnology, Department of Biotechnology, Ghent University, Ghent, Belgium.ORCID 0000-0001-7723-1040

Funding

Bijzonder Onderzoeksfonds UGent (BOF) 01P10022Fonds Wetenschappelijk Onderzoek (FWO) 1S15424N
6 · The paper itself

Abstract

Phage lysins, bacteriophage-encoded enzymes tasked with degrading their host's cell wall, are increasingly investigated and engineered as novel antibacterials across diverse applications. Their rapid action, tuneable specificity, and low likelihood of resistance development make them particularly interesting. Despite numerous application-focused lysin studies, the art of their recombinant production remains relatively undiscussed. Here, we provide an overview of the available expression systems for phage lysin production and discuss key considerations guiding the choice of a suitable recombinant host. We systematically surveyed recent literature to evaluate the hosts used in the lysin field and cover various recombinant systems, including the well-known bacterial host Escherichia coli or yeast Saccharomyces cerevisiae, as well as plant, mammalian, and cell-free systems. Careful analysis of the limited studies expressing lysins in various hosts suggests a host-dependent effect on activity. Nonetheless, the multitude of available expression systems should be further leveraged to accommodate the growing interest in phage lysins and their expanding range of applications.

Indexed as

BacteriophagesEscherichia coliRecombinant ProteinsSaccharomyces cerevisiaeViral ProteinsRecombinant ProteinsViral ProteinsEndolysinExpressionHost selectionPhage lysinRecombinant protein

Identifiers

PMID39290148
PMCPMC11652153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.